The PRIMO Study-Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Chronic Kidney Disease Stage 3B/4.

Trial Profile

The PRIMO Study-Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Chronic Kidney Disease Stage 3B/4.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Kidney disorders; Left ventricular hypertrophy
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms PRIMO
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Apr 2012 Actual end date changed from 24 Jun 2010 to Mar 2012 as reported by ClinicalTrials.gov.
    • 03 Mar 2012 Actual end date (Jul 2010) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top